Skip to main content
P

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 86 across all filing types
Latest filing 2026-04-21 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - PER 6 pages 18.3KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Appendix 2A “Application for quotation of securities” by Percheron Therapeutics Limited. It details the number and type of new shares/options to be quoted following a prior Appendix 3B issue. This is an announcement regarding a capital change/new share issue. Therefore it falls under the Share Issue/Capital Change category (SHA).
2026-04-21 English
Notification regarding unquoted securities - PER 5 pages 17.0KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Appendix 3G announcement detailing the issue of unquoted equity securities, including number issued, issue price, and total securities on issue. This is a notification of share issuance/capital change rather than a full report, earnings release, or other governance material. It directly corresponds to the Share Issue/Capital Change category.
2026-04-21 English
New HMBD-002 Data Presented at AACR Annual Meeting 4 pages 1.1MB
Regulatory Filings Classification · 1% confidence The document is an ASX announcement presenting clinical trial data (a conference poster) with detailed scientific study methods and results, not a financial report, earnings release, or any corporate governance or transaction notice. It does not match any specialized filing category (10-K, ER, IR, MDA, IP, etc.), so it defaults to the general “Regulatory Filings” fallback category.
2026-04-20 English
Application for quotation of securities - PER 6 pages 18.4KB
Regulatory Filings
2026-04-14 English
Notification regarding unquoted securities - PER 5 pages 17.2KB
Regulatory Filings
2026-04-14 English
Change of Director's Interest Notice 3 pages 223.1KB
Regulatory Filings
2026-04-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.